In two phase 3 trials (273 people with narcolepsy type 1), oveporexton vs placebo improved MWT sleep latency at 12 weeks (+14.3 to 19.8 vs −0.4 to −0.8 min), with gains in sleepiness and cataplexy; adverse events 86–89% vs 43–54%.
RCTn = 273
Dauvilliers et al. Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials